Forslöw Ulrica, Mattsson Jonas, Ringden Olle, Klominek Julius, Remberger Mats
Department of Medicine, Division of Respiratory Medicine and Allergology, Huddinge, Sweden.
Scand J Infect Dis. 2006;38(11-12):970-6. doi: 10.1080/00365540600786481.
Pulmonary complications after allogeneic hematopoietic stem-cell transplantation (HSCT) remain 1 of the most important causes of morbidity and mortality. This study evaluates the change over time of incidence, aetiology and risk factors for death related to pneumonia within 3 months after HSCT. 997 patients who underwent HSCT were studied retrospectively. Most patients (83%) had a haematological malignancy. The majority (89%) had an HLA-A, -B, and -DR matched related or unrelated donor. Conditioning consisted of cyclophosphamide and total-body irradiation or busulfan and graft-versus-host disease prophylaxis of cyclosporin and methotrexate in most cases. Death related to pneumonia occurred in 56 (5.6%) patients. Cytomegalovirus (37%) was the main pathogen involved, especially during the first 2 decades studied. In the multivariate risk factor analysis, we found that death from pneumonia was significantly associated with receiving a T-cell depleted graft (p<0.001), bacteraemia (p=0.001), and y of transplantation (p<0.001). In patients receiving a transplant during the last decade, the incidence of death related to pneumonia was 2.8% compared to 8.9% during the first decade. We conclude that the rate of mortality related to pneumonia has decreased over time, possibly as a result of improved diagnostic, prophylactic and therapeutic methods and treatment.
异基因造血干细胞移植(HSCT)后的肺部并发症仍然是发病和死亡的最重要原因之一。本研究评估了HSCT后3个月内与肺炎相关的发病率、病因及死亡风险因素随时间的变化。对997例行HSCT的患者进行了回顾性研究。大多数患者(83%)患有血液系统恶性肿瘤。大多数(89%)患者有HLA - A、- B和 - DR匹配的相关或无关供体。预处理方案在大多数情况下包括环磷酰胺和全身照射或白消安,以及用环孢素和甲氨蝶呤预防移植物抗宿主病。56例(5.6%)患者死于肺炎。巨细胞病毒(37%)是主要的致病原,尤其是在研究的前20年。在多因素风险因素分析中,我们发现肺炎死亡与接受T细胞去除的移植物(p<0.001)、菌血症(p = 0.001)及移植年份(p<0.001)显著相关。在过去十年接受移植的患者中,与肺炎相关的死亡率为2.8%,而在第一个十年为8.9%。我们得出结论,与肺炎相关的死亡率随时间有所下降,这可能是诊断、预防和治疗方法及治疗改善的结果。